

**Filed On Behalf Of:**  
Novartis AG

**By:**  
Nicholas N. Kallas  
NKallas@Venable.com  
ZortressAfinitorIPR@Venable.com  
(212) 218-2100

**UNITED STATES PATENT AND TRADEMARK OFFICE**

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

**ARGENTUM PHARMACEUTICALS LLC, and WEST-WARD  
PHARMACEUTICALS INTERNATIONAL LIMITED,  
Petitioners,**

v.

**NOVARTIS AG,  
Patent Owner.**

---

Case IPR2016-01479<sup>1</sup>  
Patent No. 9,006,224 B2

**PATENT OWNER'S THIRD UPDATED MANDATORY  
NOTICES UNDER 37 C.F.R. § 42.8(a)(3)**

---

<sup>1</sup> IPR2017-01063 and IPR2017-01078 have been joined to this proceeding (Paper 33, September 25, 2017). Par Pharmaceutical Inc. has been terminated as a party to this proceeding (Paper 52, February 7, 2018).

Pursuant to the requirements of 37 C.F.R. § 42.8(a)(3), Novartis AG (“Novartis” or “Patent Owner”) submits the following update to its July 24, 2018 Second Updated Mandatory Notices (Paper No. 54).

**REAL PARTY-IN-INTEREST PURSUANT TO 37 C.F.R. § 42.8(b)(1)**

The real party-in-interest information has not changed.

**RELATED MATTERS PURSUANT TO 37 C.F.R. § 42.8(b)(2)**

The related matters information has not changed.

**IDENTIFICATION OF LEAD AND BACK-UP COUNSEL  
PURSUANT TO 37 C.F.R. §§ 42.8(b)(3) and 42.10**

The lead and back-up counsel have not changed, however, Novartis reports a change of firm name for lead and back-up counsel from Fitzpatrick, Cella, Harper & Scinto to Venable LLP. The contact information for lead and back-up counsel has changed as follows:

Lead Counsel	Nicholas N. Kallas (Reg. No. 31,530) VENABLE LLP 1290 Avenue of the Americas New York, NY 10104-3800 Tel. 212-218-2100 NKallas@Venable.com
Back-Up Counsel	Laura K. Fishwick (Reg. No. 69,907) VENABLE LLP 1290 Avenue of the Americas New York, NY 10104-3800 Tel. 212-218-2100 LFishwick@Venable.com

The contact information for back-up counsel Peter J. Waibel (Reg. No. 43,228) and Gregory D. Ferraro (Reg. No. 36,134) remains the same.

**SERVICE INFORMATION PURSUANT TO 37 C.F.R. § 42.8(b)(4)**

The service information for counsel for Novartis has changed. Novartis may be served electronically using the following e-mail address:

ZortressAfinitorIPR@Venable.com

Novartis may be served by postal mailing, hand-delivery, telephone or facsimile as follows:

Nicholas N. Kallas  
Venable LLP  
1290 Avenue of the Americas  
New York, NY10104  
Telephone: (212) 218-2100  
Facsimile: (212) 218-2200

Respectfully submitted,

Dated: November 14, 2018

/ Nicholas N. Kallas /  
Nicholas N. Kallas  
Registration No. 31,530  
Lead Counsel for Patent Owner  
VENABLE LLP  
1290 Avenue of the Americas  
New York, NY 10104-3800  
Tel. 212-218-2100

## CERTIFICATE OF SERVICE

I certify that a copy of Patent Owner's Third Updated Mandatory Notices Under 37 C.F.R. § 42.8(a)(3) was served on November 14, 2018 by causing it to be sent by email to counsel for Petitioners at the following email addresses:

Kevin Laurence (klaurence@lpiplaw.com)

Matthew Phillips (mphilips@lpiplaw.com)

Tyler C. Liu (tliu@agpharm.com)

Keith A. Zullo (kzullo@goodwinprocter.com)

Marta E. Delsignore (mdelsignore@goodwinprocter.com)

Dated: November 14, 2018

/ Nicholas N. Kallas /  
Nicholas N. Kallas  
Registration No. 31,530  
VENABLE LLP  
1290 Avenue of the Americas  
New York, NY 10104-3800  
Tel. 212-218-2100